Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506655 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL16290419 | 0.84 | — | — | |
| SCHEMBL20427569 | 0.82 | MAN1B1 (0.33) | — | |
| SCHEMBL6522918 | 0.82 | MAN1B1 (0.33) | — | |
| SCHEMBL31759463 | 0.82 | — | — | |
| SCHEMBL19343707 | 0.82 | — | — | |
| SCHEMBL18663771 | 0.82 | MAN1B1 (0.33) | — | |
| SCHEMBL6522910 | 0.82 | MAN1B1 (0.33) | — | |
| SCHEMBL15887089 | 0.82 | — | — | |
| SCHEMBL31759459 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-114364667-B | 3-Substituted piperidines for Cbl-b inhibition and use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11464802-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114364667-A | 3-substituted piperidines for Cbl-b inhibition and the use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3953346-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | Nurix Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017155735-A1 | AMINE-CONTAINING CYCLIC HYDROFLUOROETHERS AND METHODS OF USING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155686-A1 | AMINE-CONTAINING ACYCLIC HYDROFLUOROETHERS AND METHODS OF USING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2678315-B1 | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2678315-B1 | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2678315-A2 | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | Janssen Pharmaceutica, N.V. (BE) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012113850-A2 | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-30 | — | — | WO | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| WO-2008098859-A1 | HCV POLYMERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378839-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | CCR5 1802/4885CHRNB2 2950/4885CHRNA4 4001/4885 |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CCR5 1802/4885CHRNB2 2950/4885CHRNA4 4001/4885 |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | CCR5 480/4885CHRNB2 4885/4885CHRNA4 4854/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CCR5 1802/4885CHRNB2 2950/4885CHRNA4 4001/4885 |
| US-11464802-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CCR5 1802/4885CHRNB2 2950/4885CHRNA4 4001/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | CCR5 504/4885CHRNB2 4839/4885CHRNA4 4814/4885 |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | CCR5 1802/4885CHRNB2 2950/4885CHRNA4 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.